Confidence in evidence summarized in meta-analyses depends on the strength of the underlying studies. This inherent limitation of syntheses appears in the case of a meta-analysis of sodium-glucose cotransporter 2 inhibitors for the treatment of type 2 diabetes because many of the pertinent randomized trials did not handle patient dropout and "rescue" medication properly. Repudiated statistical methods, such as last observation carried forward, and unsophisticated methods for handling postrescue data produce unreliable summary estimates. Future reports of randomized studies and meta-analyses of those studies must focus on posing precise questions about the treatment effect of interest and then implement appropriate statistical methods to account for missing data, patient dropout, and use of rescue medication.
M
eta-analysis cannot provide meaningful summary estimates if the individual studies do not report results from unbiased analyses targeted to clinical questions of greatest interest. One important and often neglected source of bias is the handling of missing data. Inappropriate approaches, such as last observation carried forward (LOCF), are particularly problematic because the direction of potential bias is not predictable. How one handles missing data also affects the ability to answer particular clinical questions that investigators pose. In this article, we use an example of a meta-analysis to explicate these issues. We show that systematic reviews must go beyond simply reporting the extent of missing data in original studies-they must also evaluate methods used to handle such data and examine outcome information collected after patients discontinued or switched assigned therapies.
THE EXAMPLE
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs for treatment of type 2 diabetes that block reabsorption of glucose in renal tubules and increase its excretion in urine. The U.S. Food and Drug Administration and the European Medicines Agency each recently approved a drug in this class (canagliflozin and dapagliflozin, respectively) for patients with type 2 diabetes who do not have severe renal impairment. Pharmaceutical companies have submitted applications for approval of ipragliflozin and empagliflozin in Japan and the United States, respectively, and are developing several other SGLT2 inhibitors. Some analysts herald these agents as the new blockbusters in the treatment of type 2 diabetes, but what does the current evidence show us about the benefits and harms of these agents?
This issue of Annals features a meta-analysis of 58 trials that compared an SGLT2 inhibitor with placebo (45 studies) or another antidiabetic drug (13 studies) (1). The trials were parallel double-blind studies with durations ranging from 4 to 52 weeks. Some allowed for long-term extensions of 26 to 80 weeks. In placebo-controlled trials longer than 12 weeks, patients who did not meet prespecified glycemic targets received "rescue" medication with another hypoglycemic agent. Specific targets and rescue medications varied by trial.
The trials as reported showed that SGLT2 inhibitors reduced hemoglobin A 1c (HbA 1c ) levels, blood pressure, and weight; had glycemic efficacy similar to that of other antidiabetic agents; and increased the incidence of genital and urinary tract infections. Effects on cardiovascular outcomes were inconclusive. There was a weak signal for possible increased risk for nonfatal stroke with canagliflozin and for cancer (bladder and breast) with dapagliflozin.
In the meta-analysis, Vasilakou and colleagues used the Grading of Recommendations Assessment, Development and Evaluation approach to assess confidence in the summarized evidence (2) and the Cochrane risk-of-bias tool (3) to evaluate the validity of individual trials. The former considers randomized trials to be high-quality evidence unless trial data are biased, inconsistent, imprecise, or indirect. It notes that bias can arise from any of several issues, including incomplete accounting of patients or outcome events or failure to adhere to the "intention-to-treat principle," but it offers no specific guidance for assessing methods of handling loss to follow-up (4). The Cochrane tool considers trials to be at high risk of bias if dropout rates are unbalanced between treatment groups or are more than 20%; reasons for dropouts are not clearly described;
inappropriate analyses, such as per-protocol analysis, are done; or an inappropriate imputation method, such as LOCF, is used to handle missing data. Using these methods, Vasilakou and colleagues downgraded the evidence about the effects of SGLT2 inhibitors on several outcomes, including HbA 1c level, because most trials showed high risk of bias.
LOW-QUALITY EVIDENCE DUE TO MISSING DATA AND INAPPROPRIATE ANALYSIS
Most of the 58 trials of SGLT2 inhibitors had high or imbalanced rates of attrition and used LOCF imputation for incomplete outcome data. In an LOCF analysis, missing outcomes are assumed to equal the last observed value. This method is often used when patients who are followed over time do not reach the end of a study. Last measurements, whenever they occur, are deemed the final measurements for analysis and are treated as if they were outcomes at the end of follow-up. This method for handling missing data, dropout, or differential duration of follow-up has been strongly criticized in the statistical literature because it can result in bias of unknown direction and in understated estimates of variance (5) . Variance estimates are too low because the values carried forward are treated as if the final outcomes were observed and known with certainty. Furthermore, this approach can generate estimates that do not address the original clinical questions that were posed.
Authors of most of the placebo-controlled trials in the SGLT2 inhibitor review applied LOCF to true missing data due to dropout and to "missingness" created by handling patients treated with rescue medications as though they had dropped out. Figure 1 depicts such use of LOCF for a hypothetical 24-week study. The top panel depicts a patient who discontinues the trial because of an adverse event and has no HbA 1c measurements after week 12. The bottom panel depicts a patient who is rescued at week 12 and shows 2 possible trajectories of postrescue HbA 1c measurements after week 12 that are "excluded" (assumed to be missing or censored). In both examples, the value at week 12 is assumed to equal the final 24-week outcome. For the placebo-controlled trials included in the meta-analysis of HbA 1c values, completion rates varied from 69% to 96% with placebo and from 81% to 100% with SGLT2 inhibitors. Rates of rescue varied from 7% to 41% with placebo and from 0% to 15% with SGLT2 inhibitors. One longterm extension trial had even lower completion rates (53% for placebo and 69% for dapagliflozin) and higher rates of rescue (61% for placebo and 42% for dapagliflozin) (6) .
Although most published reports provided results only from LOCF analyses, 3 trials reported both an LOCF analysis and a mixed-effects model fit to all observed data, including postrescue data. Results from 2 of these trials were reported as part of sensitivity analyses presented in a U.S. Food and Drug Administration briefing document for dapagliflozin (7), and results from the other trial were provided in an appendix table (8) . Durations ranged from 24 to 48 weeks. For these 3 trials, the LOCF result was least conservative, showing between-group differences in HbA 1c reductions of 0.66%, 0.54%, and 0.60%, whereas the respective reductions from a mixed-effects model were 0.45%, 0.44%, and 0.57% (7, 8) .
Differences between the LOCF and mixed-effects model results were created by the inclusion of postrescue data and the different handling of missing data due to dropout. A mixed-effects model is a type of regression approach that properly handles repeated measurements from individuals over time and does not require complete data. In this context, a mixed-effects model fit to all observed data provides an intention-to-treat effect estimate (comparing the effect of SGLT2 inhibitors with rescue and the effect of placebo with rescue). It assumes that missing data due to dropout are missing at random (that is, missingness is unrelated to what would happen to that patient in the future) (9).
IMPLICATIONS FOR THE SGLT2 INHIBITOR META-ANALYSIS
When meta-analyses include studies with results based on LOCF, the validity of the overall pooled estimates is suspect. Most of the placebo-controlled SGLT2 inhibitor trials had imbalanced rates of rescue in addition to some attrition and used LOCF to handle both (Supplement 1, available at www.annals.org). Potential bias in the overall treatment effect estimate for HbA 1c level reported in FigFigure 1 . Use of LOCF to handle dropouts and excluded data after rescue. The data are from a hypothetical 24-wk study and show the use of LOCF in a patient who discontinues the trial because of an adverse event and has no HbA 1c measurements after week 12 (top) and in a patient who is rescued at week 12 and has HbA 1c measurements after rescue (2 possible trajectories are shown) that are excluded from the analysis (bottom). HbA 1c ϭ hemoglobin A 1c ; LOCF ϭ last observation carried forward.
ure 2 of Vasilakou and colleagues' article depends on the amounts of dropout and rescue in the 26 pertinent placebo-controlled trials and the degree to which the LOCF results in individual trials might be biased. We examined the sensitivity of the reported pooled change in HbA 1c level to small, medium, and large biases that LOCF might produce, assuming biases similar to those found in the 3 trials with results from both an LOCF analysis and a mixed-effects model (under a missing-atrandom assumption). In addition to this bias, because LOCF results underestimate variances, the validity of the pooled results is further compromised. We therefore expanded SEs by 10% to 50% using values taken from the 3 trials. The results in Figure 2 show strong attenuation of the original LOCF meta-analytic estimate (Ϫ0.66%) when medium to large LOCF biases are introduced. With a large LOCF bias (around 50%), the treatment effect estimate decreased substantially, to Ϫ0.46%. The 95% CI did not overlap the CI derived from the LOCF analysis, indicating statistically different estimates between the 2 approaches.
Mixed-effects modeling approaches work best when the missing-at-random assumption is appropriate. However, these approaches can be problematic when missingness is nonrandom or informative about future outcomes, as in the case when rescue medications are used because of low treatment efficacy. For example, LOCF biases could be large for dropouts but negligible for patients who receive rescue medication (that is, no difference in HbA 1c effects between treatment and placebo groups for patients requiring rescue medication). When we incorporated a negligible bias for patients who received rescue medication, we obtained pooled estimates similar to those obtained with LOCF (Ϫ0.68% [95% CI, Ϫ0.76% to Ϫ0.59%]). Additional details about these methods, including the data and code, are provided in Supplements 2 and 3 (available at www.annals.org).
Our aim was to examine how much the assumptions and analytic choices affect meta-analytic results and strength of conclusions when studies with high amounts of missing data are handled using LOCF. On the basis of these simple approaches, we see how results can be sensitive to the method used to handle missing data. Other approaches are available, such as Bayesian techniques (10, 11) or down-weighting of individual studies with high levels of missingness.
MOVING FORWARD WITH CONTEMPORARY STATISTICAL METHODS
If a meta-analysis can compound the analytic problems in the underlying studies, a solution lies in improving statistical methods for those studies. Although these longitudinal studies of SGLT2 inhibitors randomly assigned treatment at baseline, the studies lose the full benefits of that randomization when patients drop out, are lost to follow-up, do not adhere fully to the assigned treatment, or require rescue therapy. A simple first step to understanding what is being compared in randomized trials that are actually more similar to longitudinal observational studies would be a clear description of the number of preplanned measurements obtained from each patient and the number of patients successfully measured at each follow-up time. To evaluate the extent to which treatment groups remain comparable, the meta-analyst also needs detailed information on the number of patients who dropped out or terminated or switched treatment and the trajectories of their outcomes when receiving assigned therapy.
Meta-analysts and investigators need clearly articulated questions and an understanding of whether analytic approaches are appropriate for those questions. The common intention-to-treat (or as-randomized) analysis compares the effect of treatment assignment, regardless of whether the patient actually took the medication, adhered to the protocol, or required rescue. For as-randomized analyses, mixed-effects models and generalized estimating equations can be used. These methods are well-described in modern textbooks (12) , make use of all available data from each patient, and perform better than analysis of variance with data imputations using LOCF (13) .
Longitudinal analytic methods can be adapted to adjust for censoring from dropout, switching to rescue medication (14) , or failure to adhere to protocol (15) (16) (17) (18) . These approaches answer such questions as "What would be the effect if patients took the assigned medication continuously?" or "Would treatment improve outcome if rescue medication were permitted only among the intervention patients?" (14) . Sensitivity analysis allowing for the possibility that dropout is related to future unobserved outcomes can follow standard statistical approaches (5). With The degree of LOCF bias is given relative to an analysis under a missingat-random assumption. Estimates assume 10% expanded SEs. Values in parentheses are 95% CIs. HbA 1c ϭ hemoglobin A 1c ; LOCF ϭ last observation carried forward.
improved descriptions of study design, patient follow-up, and statistical analysis, the systematic review could separate studies not only by purpose of treatment (monotherapy vs. add-on) or patient characteristic (male vs. female) but also by the questions posed and answered.
WHERE TO GO FROM HERE
Having an entire body of evidence considered lowquality or inconclusive due to inadequate treatment of missing data is not new (19, 20) . The challenge is how to change course as old studies mature and new investigations begin. Data about SGLT2 inhibitors are rapidly accumulating. The meta-analysis authors found 25 additional completed trials that they could not include because results were pending or undisclosed, and more trials are planned. As ongoing studies lengthen follow-up and extend to such outcomes as cardiovascular events and death, the benefits of the randomized design can attenuate and the influence on treatment effects of dropout or postrandomization rescue medications or ancillary treatments will expand.
Reliance on repudiated methods must give way to demonstrably better statistical methods. Authors should clearly articulate the clinical questions of interest and then closely link them to their statistical methods. They must describe the frequency of and reasons for dropout and rescue medication, the heterogeneity of responses to rescue treatments, and the statistical methods for handling these departures from baseline randomization.
Interpretation of the current evidence base for SGLT2 inhibitors is tarnished by reliance on LOCF to adjust for patient dropout and rescue. Attempting to account for multiple sources of missing data at the time of metaanalysis is difficult. Results of such exercises are dependent on unverifiable assumptions. If original studies do not use proper methods, reliable pooling will only be possible if investigators and sponsors provide individual-patient data to support reanalysis. Now is the time to move forward and stop carrying forward.
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